Flexible ligated ruthenium(II) self-assemblies sensitizes glioma tumor initiating cells in vitro
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Elumalai, Palani | - |
dc.contributor.author | Kaushik, Neha | - |
dc.contributor.author | Kim, Dong Hwan | - |
dc.contributor.author | Kim, Hyunuk | - |
dc.contributor.author | Lee, Su Jae | - |
dc.contributor.author | Choi, Eun Ha | - |
dc.contributor.author | Chi, Ki-Whan | - |
dc.contributor.author | Kaushik, Nagendra Kumar | - |
dc.date.accessioned | 2021-08-02T14:51:05Z | - |
dc.date.available | 2021-08-02T14:51:05Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2017-09 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/19418 | - |
dc.description.abstract | The tumorigenic potentials of residual cancer stem-like cells within tumors represent limitations of current cancer therapies. Here, the authors describe the effects of synthesized flexible, ligated, supramolecular self-assembled chair type tetranuclear ruthenium (II) metallacycles (2-5) on glioblastoma and glioma stem like cells. These self-assemblies were observed to be selectively toxic to glioma cells and CD133-positive glioma stem like cells population. Of the self-assembled compounds tested, metallacycle 4 more efficiently induced glioma stem like cells death within a brain cancer cell population and simultaneously inhibited the formation of free-floating gliospheres by reducing the sphere size. Detailed cell death studies revealed that treatment with metallacycle 4 reduced mitochondrial membrane potentials (an indicator of apoptosis) of glioma stem like cells. These results shows the elimination of cancer stem-like cells using an appropriate ligand binding adaptor offers a potential means of developing metal-based compounds for the treatment of chemo-resistant tumors. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | Flexible ligated ruthenium(II) self-assemblies sensitizes glioma tumor initiating cells in vitro | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Su Jae | - |
dc.identifier.doi | 10.18632/oncotarget.19028 | - |
dc.identifier.scopusid | 2-s2.0-85030479542 | - |
dc.identifier.wosid | 000408944300014 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.8, no.36, pp.60188 - 60200 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 8 | - |
dc.citation.number | 36 | - |
dc.citation.startPage | 60188 | - |
dc.citation.endPage | 60200 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | SELECTIVE SYNTHESIS | - |
dc.subject.keywordPlus | COMPLEXES | - |
dc.subject.keywordPlus | PLASMA | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | SOLVENT | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | METALLACAGES | - |
dc.subject.keywordPlus | MEDICINE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | self-assembly | - |
dc.subject.keywordAuthor | flexible ligand | - |
dc.subject.keywordAuthor | arene-ruthenium | - |
dc.subject.keywordAuthor | metallacycle | - |
dc.subject.keywordAuthor | solid cancer | - |
dc.identifier.url | https://www.oncotarget.com/article/19028/text/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.